AQUESTIVE THERAPEUTICS INC

Insight into AQUESTIVE THERAPEUTICS insider trades: Sherry Korczynski’s balanced buys and option sales signal confidence amid a 52‑week low, guiding investors on potential upside and risk management.

CEO Barber Daniel sells 25,000 shares of Aquestive Therapeutics—insider selling trend hints at potential caution over near‑term prospects.

Insider sale by AQUESTIVE’s COO sparks buzz but little impact – market stays bullish on its CNS pipeline, showing routine liquidity move, not a warning.

CEO Daniel Barber’s July 2026 AQUESTIVE THERAPEUTICS sell‑off shows routine liquidity management amid a sliding stock, not a bearish warning.

Julie Krop’s 10(b)(5)(1) buy‑sell move shows disciplined liquidity management and long‑term confidence in AQUESTIVE’s CNS therapeutics pipeline.

CEO Barber Daniel sells 25k shares of AQT at $4.16 – insider trades hint at liquidity needs but long‑term confidence in this biotech’s pipeline.

Insider buying spurs bullish outlook for Aquestive, with senior execs securing 50,500 stock options—signaling confidence in the company’s CNS pipeline and future growth prospects.

Insightful insider sales at Aquestive Therapeutics reveal routine equity management, yet the company’s bullish pipeline and 89.5% YTD rally signal cautious optimism for investors.